Guidelines Update
- 1 January 2000
- journal article
- guideline
- Published by Springer Nature in Drugs
- Vol. 59 (Supplement) , 23-28
- https://doi.org/10.2165/00003495-200059001-00004
Abstract
The new leukotriene (LT) modifiers have been shown to be effective, safe and convenient ‘controller’ medications in patients with asthma. However, their use in asthma is recommended only in the most recent US guidelines, and then only as alternative long term controllers in patients with mild persistent asthma. In fact, as has now been shown in a number of studies, LT modifiers are effective in a variety of other asthma settings, and it is expected that expanded roles for these agents will be described in future asthma guidelines. Until then, clinicians aware of the advantages of individualising asthma therapy might consider LT modifiers for the diverse range of patients with asthma who are likely to benefit from the use of these agents.Keywords
This publication has 22 references indexed in Scilit:
- Algorithm for the Diagnosis and Management of Asthma: a Practice Parameter Update: These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and ImmunologyAnnals of Allergy, Asthma & Immunology, 1998
- Preventive Pharmacologic Therapy Among Asthmatics: Five Years After Publication of GuidelinesAnnals of Allergy, Asthma & Immunology, 1998
- ZafirlukastDrugs, 1998
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Comparison of guidelines and self-management plans in asthmaEuropean Respiratory Journal, 1997
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997
- National and international guidelines for the diagnosis and treatment of asthmaCurrent Opinion in Pulmonary Medicine, 1997
- Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trialJournal of Allergy and Clinical Immunology, 1996
- The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to AspirinAmerican Review of Respiratory Disease, 1993
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991